{
  "abstract": "Successful immune checkpoint inhibitor (ICI) treatment of cancer requires adequate infiltration of cytotoxic CD8+T lymphocytes (CTLs) in tumors. Previous studies have identified the compound naringin, which increases CTL infiltration and rescues ICI efficacy in CTL-lacking tumors, and cancer CTL priming has been shown to rely on antigen cross-presentation (XPT). Therefore, the present study aimed to examine the effect of naringin on XPT by various human and murine antigen-presenting cells (APCs). The results indicated that naringin increases XPT by XPT-competent APCs, including murine bone marrow (BM) dendritic cells, peritoneal macrophages (MΦs), and human monocyte-derived dendritic cells (HMDCs). However, XPT was not observed with BM- or human monocyte-derived MΦs with or without naringin. Naringin reduced the activity of lysosomes, suppressing the degradation of internalized antigens, thereby increasing antigen cytosolic escape and MHC class I molecule-presenting antigens. In addition, human lymph node (LN) sinus MΦs were transcriptomically more similar to XPT-competent HMDCs than other LN MΦ groups. Taken together, these data suggest that naringin promotes XPT by XPT-competent APCs, which may explain why naringin was found to promote cancer immunity in our previous studies. This finding highlights the potential for developing cancer immunotherapies that induce XPT, offering a promising strategy to enhance antitumor immune responses.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan.",
    "Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.",
    "Department of Pathology, Sapporo Medical University, Sapporo, Hokkaido, Japan.",
    "Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto, 860-8556, Japan. ycomo@kumamoto-u.ac.jp.",
    "Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Kumamoto, Japan. ycomo@kumamoto-u.ac.jp."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Cheng Pan"
    },
    {
      "affs": [
        0
      ],
      "name": "Yukio Fujiwara"
    },
    {
      "affs": [
        0
      ],
      "name": "Daiki Yoshii"
    },
    {
      "affs": [
        0
      ],
      "name": "Jiahao Pan"
    },
    {
      "affs": [
        1
      ],
      "name": "Takuya Shiota"
    },
    {
      "affs": [
        1
      ],
      "name": "Yuko Miyasato"
    },
    {
      "affs": [
        2
      ],
      "name": "Yuka Mizue"
    },
    {
      "affs": [
        2
      ],
      "name": "Yoshihiko Hirohashi"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Yoshihiro Komohara"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9t13g3n017esc.bib",
  "cited_by": 0,
  "doi": "10.1007/s00262-026-04497-7",
  "fulltext_url": "https://europepmc.org/articles/PMC13687496",
  "id": "9t13g3n017esc",
  "issns": [
    "0340-7004",
    "1432-0851"
  ],
  "landing_url": "https://europepmc.org/article/MED/42907578",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2403|Immunotherapy and Immune Responses"
    ]
  ],
  "openalex": "W7171319429",
  "pdf_url": "https://europepmc.org/articles/PMC13687496?pdf=render",
  "pmcid": "PMC13687496",
  "pmid": "42907578",
  "published": "2026-07-01",
  "publisher": "Springer",
  "ris": "https://research.draconitic.com/paper/9t13g3n017esc.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:57Z",
      "native_id": "MED:42907578",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42907578"
    },
    {
      "first_seen": "2026-10-30T13:46:06Z",
      "native_id": "c9f96248cf924a8a87cc27d653fea180",
      "source": "doaj",
      "url": "https://doi.org/10.1007/s00262-026-04497-7"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Immunotherapy and Immune Responses",
      "subfield": "immunology"
    }
  ],
  "title": "Naringin promotes cancer immunity by inducing cross-presentation by antigen-presenting cells.",
  "title_text": "Naringin promotes cancer immunity by inducing cross-presentation by antigen-presenting cells.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T13:46:06Z",
  "url": "https://research.draconitic.com/paper/9t13g3n017esc",
  "venue": "Cancer immunology, immunotherapy : CII",
  "versions": []
}